{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:09:32Z","timestamp":1763028572918,"version":"3.45.0"},"reference-count":133,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM138303"],"award-info":[{"award-number":["R35GM138303"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Chronic inflammation constitutes a significant characteristic of sustained infections caused by viral and fungal pathogens, with a strong correlation to the development of cancer, autoimmune disorders, and tissue fibrosis. Viral proteins such as HIV-1 Tat, HBV X (HBx), HPV E6\/E7, and EBV LMP1 modulate the host\u2019s immune signaling pathways, primarily through the activation of the NF-\u03baB signaling cascade and the disruption of cytokine equilibrium. These molecular interactions result in a pro-inflammatory microenvironment that facilitates viral persistence, immune evasion, and the process of oncogenesis. Structural investigations have elucidated the mechanisms by which these viral proteins interact with host signaling complexes, thereby highlighting their potential as viable therapeutic targets. Similarly, fungal proteins, including secreted aspartyl proteases (Saps), ribotoxin Asp f1, and chitin-binding proteins, incite chronic inflammation by activating pattern recognition receptors and triggering inflammasome activation. Despite the limited structural information of these fungal proteins, emerging models and bioinformatic analyses identified conserved motifs that are crucial for host interactions. Biologic therapies, encompassing antiviral and antifungal peptides as well as monoclonal antibodies, are currently under development to disrupt these protein-host interactions and modulate inflammatory responses. This review provides structural and functional insight into viral and fungal inflammatory proteins and evaluates the potential of biologics as targeted therapeutic interventions for chronic inflammation associated with infections. We discuss the ongoing clinical trials involving neutralizing antibodies targeting HIV, peptide vaccines aimed at HPV and other promising molecules. Finally, we discuss the current limitations of biologics and possible solutions to translate these promising therapeutics into clinical practice.<\/jats:p>","DOI":"10.3390\/pharmaceutics17111466","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:59:09Z","timestamp":1763027949000},"page":"1466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural and Functional Insights into Viral and Fungal Proteins Involved in Chronic Inflammation and Their Biologic Treatments"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-7479","authenticated-orcid":false,"given":"Mohamed","family":"Halawa","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School, Rowan University, Camden, NJ 08103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia L.","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School, Rowan University, Camden, NJ 08103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-0556","authenticated-orcid":false,"given":"Valerie J.","family":"Carabetta","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School, Rowan University, Camden, NJ 08103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., and Tang, H. (2022). Chronic inflammation, cancer development and immunotherapy. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1040163"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00018-025-05575-2","article-title":"Activation and evasion of inflammasomes during viral and microbial infection","volume":"82","author":"Ren","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tugizov, S. (2025). HIV-1 Tat-induced disruption of epithelial junctions and epithelial-mesenchymal transition of oral and genital epithelial cells lead to increased invasiveness of neoplastic cells and the spread of herpes simplex virus and cytomegalovirus. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1541532"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lien, K., Mayer, W., Herrera, R., Padilla, N.T., Cai, X., Lin, V., Pholcharoenchit, R., Palefsky, J., and Tugizov, S.M. (2022). HIV-1 Proteins gp120 and Tat Promote Epithelial-Mesenchymal Transition and Invasiveness of HPV-Positive and HPV-Negative Neoplastic Genital and Oral Epithelial Cells. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.03622-22"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1038\/sj.onc.1202144","article-title":"Epstein\u2013Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions","volume":"17","author":"Floettmann","year":"1998","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Das, B., Sarkar, C., Rawat, V.S., Kalita, D., Deka, S., and Agnihotri, A. (2021). Promise of the NLRP3 inflammasome inhibitors in in vivo disease models. Molecules, 26.","DOI":"10.3390\/molecules26164996"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1172\/JCI120845","article-title":"Mitochondrial fidelity and metabolic agility control immune cell fate and function","volume":"128","author":"Sack","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/embr.201337983","article-title":"The I\u03baB kinase complex in NF-\u03baB regulation and beyond","volume":"15","author":"Hinz","year":"2014","journal-title":"EMBO Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lien, K., Mayer, W., Herrera, R., Rosbe, K., and Tugizov, S.M. (2019). HIV-1 proteins gp120 and tat induce the epithelial\u2013mesenchymal transition in oral and genital mucosal epithelial cells. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226343"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e0015222","DOI":"10.1128\/cmr.00152-22","article-title":"Broadly neutralizing antibodies for HIV prevention: A comprehensive review and future perspectives","volume":"37","author":"Mahomed","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ofy242","DOI":"10.1093\/ofid\/ofy242","article-title":"Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART","volume":"5","author":"Riddler","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: A phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV\u2014A review","volume":"22","author":"Mahomed","year":"2025","journal-title":"AIDS Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Garcia-Rubio, R., de Oliveira, H.C., Rivera, J., and Trevijano-Contador, N. (2020). The fungal cell wall: Candida, Cryptococcus, and Aspergillus species. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02993"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12931-024-02743-z","article-title":"Dectin-1 aggravates neutrophil inflammation through caspase-11\/4-mediated macrophage pyroptosis in asthma","volume":"25","author":"Cai","year":"2024","journal-title":"Respir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1039\/D4MO00222A","article-title":"Revealing the dynamics of fungal disease with proteomics","volume":"21","author":"Sa","year":"2025","journal-title":"Mol. Omics"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lohse, M.B., Gulati, M., Craik, C.S., Johnson, A.D., and Nobile, C.J. (2020). Combination of antifungal drugs and protease inhibitors prevent Candida albicans biofilm formation and disrupt mature biofilms. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01027"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40164-025-00655-2","article-title":"Molecular mechanisms of viral oncogenesis in haematological malignancies: Perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling","volume":"14","author":"Xiao","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1093\/nar\/gkr1224","article-title":"Human immunodeficiency virus-1 Tat activates NF-\u03baB via physical interaction with I\u03baB-\u03b1 and p65","volume":"40","author":"Fiume","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/nar\/gkh289","article-title":"HIV-1 Tat directly binds to NF\u03baB enhancer sequence: Role in viral and cellular gene expression","volume":"32","author":"Dandekar","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_22","first-page":"883","article-title":"1H-13 C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein","volume":"323","author":"Opia","year":"2000","journal-title":"Comptes Rendus L\u2019acad\u00e9mie Sci.-Ser. III-Sci. Vie"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"You, H., Qin, S., Zhang, F., Hu, W., Li, X., Liu, D., Kong, F., Pan, X., Zheng, K., and Tang, R. (2022). Regulation of pattern-recognition receptor signaling by HBX during hepatitis B virus infection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.829923"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Schollmeier, A., Glitscher, M., and Hildt, E. (2023). Relevance of HBx for hepatitis B virus-associated pathogenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054964"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1126\/science.1229934","article-title":"Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins","volume":"339","author":"Zanier","year":"2013","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1038\/sj.onc.1209584","article-title":"Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7","volume":"25","author":"Seiboth","year":"2006","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"\u0160imi\u010di\u0107, P., Batovi\u0107, M., Stojanovi\u0107 Markovi\u0107, A., and \u017didovec-Lepej, S. (2024). Deciphering the role of Epstein\u2013Barr virus latent membrane protein 1 in immune modulation: A multifaced Signalling perspective. Viruses, 16.","DOI":"10.3390\/v16040564"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lim, K.-H., Choi, H.S., Park, Y.K., Park, E.-S., Shin, G.C., Kim, D.H., Ahn, S.H., and Kim, K.-H. (2013). HBx-induced NF-\u03baB signaling in liver cells is potentially mediated by the ternary complex of HBx with p22-FLIP and NEMO. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057331"},{"key":"ref_29","first-page":"753","article-title":"Unfolding HBx for an epigenetic switch of HBV cccDNA minichromosome","volume":"16","author":"Liu","year":"2025","journal-title":"Protein Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13027-024-00581-8","article-title":"Emerging paradigms: Unmasking the role of oxidative stress in HPV-induced carcinogenesis","volume":"19","author":"Letafati","year":"2024","journal-title":"Infect. Agents Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41417-023-00682-3","article-title":"HPV E6\/E7: Insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor","volume":"31","author":"Peng","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1128\/JVI.01942-05","article-title":"Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner","volume":"80","author":"James","year":"2006","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Carrillo-Beltr\u00e1n, D., Mu\u00f1oz, J.P., Guerrero-V\u00e1squez, N., Blanco, R., Le\u00f3n, O., de Souza Lino, V., Tapia, J.C., Maldonado, E., Dubois-Camacho, K., and Hermoso, M.A. (2020). Human Papillomavirus 16 E7 promotes EGFR\/PI3K\/AKT1\/NRF2 signaling pathway contributing to PIR\/NF-\u03baB activation in oral cancer cells. Cancers, 12.","DOI":"10.3390\/cancers12071904"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Suarez, I., and Trave, G. (2018). Structural insights in multifunctional papillomavirus oncoproteins. Viruses, 10.","DOI":"10.3390\/v10010037"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/sj.onc.1201617","article-title":"The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells","volume":"16","author":"Braspenning","year":"1998","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1158\/0008-5472.CAN-09-0925","article-title":"Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin","volume":"69","author":"Spardy","year":"2009","journal-title":"Cancer research"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/scbi.2001.0410","article-title":"LMP1 structure and signal transduction","volume":"11","author":"Eliopoulos","year":"2001","journal-title":"Semin. Cancer Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kieser, A., and Sterz, K.R. (2015). The latent membrane protein 1 (LMP1). Epstein Barr Virus Volume 2: One Herpes Virus: Many Diseases, Springer.","DOI":"10.1007\/978-3-319-22834-1_4"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1568009623666230512153741","article-title":"The role of LMP1 in Epstein-Barr virus-associated gastric cancer","volume":"24","author":"Huang","year":"2024","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e0043422","DOI":"10.1128\/iai.00434-22","article-title":"Fungal mechanisms of intracellular survival: What can we learn from bacterial pathogens?","volume":"91","author":"Stuckey","year":"2023","journal-title":"Infect. Immun."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tang, J., Lin, G., Langdon, W.Y., Tao, L., and Zhang, J. (2018). Regulation of C-type lectin receptor-mediated antifungal immunity. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00123"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hatinguais, R., Willment, J.A., and Brown, G.D. (2020). PAMPs of the fungal cell wall and mammalian PRRs. The Fungal Cell Wall: An Armour and a Weapon for Human Fungal Pathogens, Springer.","DOI":"10.1007\/82_2020_201"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cmdc.201100490","article-title":"Experimental and computational active site mapping as a starting point to fragment-based lead discovery","volume":"7","author":"Behnen","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e00182-15","DOI":"10.1128\/mBio.00182-15","article-title":"Transcriptomic Analysis of Vulvovaginal Candidiasis Identifies a Role for the NLRP3 Inflammasome","volume":"6","author":"Bruno","year":"2015","journal-title":"mBio"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Camilli, G., Griffiths, J.S., Ho, J., Richardson, J.P., and Naglik, J.R. (2020). Some like it hot: Candida activation of inflammasomes. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008975"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"iqae010","DOI":"10.1093\/oxfimm\/iqae010","article-title":"Inflammatory cytokine signalling in vulvovaginal candidiasis: A hot mess driving immunopathology","volume":"5","author":"Cheng","year":"2024","journal-title":"Oxf. Open Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1042\/EBC20210087","article-title":"Plant immunity by damage-associated molecular patterns (DAMPs)","volume":"66","author":"Cervone","year":"2022","journal-title":"Essays Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1094\/PHYTO-03-23-0104-RVW","article-title":"Damage-associated molecular patterns and systemic signaling","volume":"114","author":"Harris","year":"2024","journal-title":"Phytopathology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dawoud, A.M., Saied, S.A., Torayah, M.M., Ramadan, A.E., and Elaskary, S.A. (2024). Antifungal susceptibility and virulence determinants profile of candida species isolated from patients with candidemia. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-61813-w"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Santos, A.L.S., Braga-Silva, L.A., Gon\u00e7alves, D.S., Ramos, L.S., Oliveira, S.S.C., Souza, L.O.P., Oliveira, V.S., Lins, R.D., Pinto, M.R., and Mu\u00f1oz, J.E. (2021). Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans\u2014In Silico, In Vitro and In Vivo Approaches. J. Fungi, 7.","DOI":"10.3390\/jof7060424"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/MMBR.67.3.400-428.2003","article-title":"Candida albicans secreted aspartyl proteinases in virulence and pathogenesis","volume":"67","author":"Naglik","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/pro.5560050408","article-title":"Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents","volume":"5","author":"Goldman","year":"1996","journal-title":"Protein Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0969-2126(01)00261-1","article-title":"The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors","volume":"3","author":"Cutfield","year":"1995","journal-title":"Structure"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nsb1101-968","article-title":"Crystal structures of restrictocin\u2013inhibitor complexes with implications for RNA recognition and base flipping","volume":"8","author":"Yang","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1074\/jbc.M407175200","article-title":"Crystal structure and binding properties of the Serratia marcescens chitin-binding protein CBP21","volume":"280","author":"Houston","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Phan, Q.T., Myers, C.L., Fu, Y., Sheppard, D.C., Yeaman, M.R., Welch, W.H., Ibrahim, A.S., Edwards, J.E., and Filler, S.G. (2007). Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol., 5.","DOI":"10.1371\/journal.pbio.0050064"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2222.2001.01076.x","article-title":"Cloning and expression of Aspergillus fumigatus allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA)","volume":"31","author":"Banerjee","year":"2001","journal-title":"Clin. Exp. Allergy"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhang, L., Sun, Y., and Zhang, Y. (2025). The Triad of Pathogenesis in Allergic Bronchopulmonary Aspergillosis: Interactions Among Aspergillus fumigatus, Epithelium, and Immunity. Int. Arch. Allergy Immunol.","DOI":"10.1159\/000547550"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature04926","article-title":"Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity","volume":"442","author":"Gross","year":"2006","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mata-Mart\u00ednez, P., Berg\u00f3n-Guti\u00e9rrez, M., and del Fresno, C. (2022). Dectin-1 signaling update: New perspectives for trained immunity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.812148"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/cmi.2010.16","article-title":"Functional characterization of the NF-kappaB binding site in the human NOD2 promoter","volume":"7","author":"Hu","year":"2010","journal-title":"Cell. Mol. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.mib.2010.05.002","article-title":"Chitin synthesis and fungal pathogenesis","volume":"13","author":"Lenardon","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wagener, J., Malireddi, R.K.S., Lenardon, M.D., K\u00f6berle, M., Vautier, S., MacCallum, D.M., Biedermann, T., Schaller, M., Netea, M.G., and Kanneganti, T.-D. (2014). Fungal Chitin Dampens Inflammation Through IL-10 Induction Mediated by NOD2 and TLR9 Activation. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004050"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Fadel, F., Zhao, Y., Cousido-Siah, A., Ruiz, F.X., Mitschler, A., and Podjarny, A. (2016). X-ray crystal structure of the full length human chitotriosidase (CHIT1) reveals features of its chitin binding domain. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154190"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11853","DOI":"10.1021\/acssuschemeng.0c03622","article-title":"Enzymatic synthesis of artificial polysaccharides","volume":"8","author":"Smith","year":"2020","journal-title":"ACS Sustain. Chem. Eng."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/21505594.2015.1012981","article-title":"Candida albicans-epithelial interactions and pathogenicity mechanisms: Scratching the surface","volume":"6","author":"Moyes","year":"2015","journal-title":"Virulence"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/s41467-025-56657-5","article-title":"Fungal Als proteins hijack host death effector domains to promote inflammasome signaling","volume":"16","author":"Zhou","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mib.2017.10.030","article-title":"Candida albicans-epithelial interactions and induction of mucosal innate immunity","volume":"40","author":"Naglik","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15775","DOI":"10.1073\/pnas.1103496108","article-title":"Structural basis for the broad specificity to host-cell ligands by the pathogenic fungus Candida albicans","volume":"108","author":"Salgado","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Halawa, M., ElSayed, R.M.R., Aderibigbe, T., Newman, P.M., Reid, B.E., and Carabetta, V.J. (2025). Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050581"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41577-022-00826-w","article-title":"Immune responses to human fungal pathogens and therapeutic prospects","volume":"23","author":"Lionakis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kwaku, G.N., Jensen, K.N., Simaku, P., Floyd, D.J., Saelens, J.W., Reardon, C.M., Ward, R.A., Basham, K.J., Hepworth, O.W., and Vyas, T.D. (2025). Extracellular vesicles from diverse fungal pathogens induce species-specific and endocytosis-dependent immunomodulation. PLoS Pathog., 21.","DOI":"10.1101\/2025.01.03.631181"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","article-title":"Viral oncogenesis in cancer: From mechanisms to therapeutics","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2017.11.003","article-title":"Human Papillomavirus E6 and E7 oncoproteins affect the cell microenvironment by classical secretion and extracellular vesicles delivery of inflammatory mediators","volume":"106","author":"Iuliano","year":"2018","journal-title":"Cytokine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","article-title":"Engineering cytokine therapeutics","volume":"1","author":"Deckers","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10989-022-10477-z","article-title":"Recent patents and FDA-approved drugs based on antiviral peptides and other peptide-related antivirals","volume":"29","author":"Maleki","year":"2022","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1570162X14999160224103908","article-title":"Inhibition of HIV entry by targeting the envelope transmembrane subunit gp41","volume":"14","author":"Yi","year":"2016","journal-title":"Curr. HIV Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2174\/1381612024607180","article-title":"Peptide and non-peptide HIV fusion inhibitors","volume":"8","author":"Jing","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrmicro3312","article-title":"Discovery of modulators of HIV-1 infection from the human peptidome","volume":"12","author":"Forssmann","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1002\/jps.24174","article-title":"Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients","volume":"103","author":"Meng","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Chong, H., Yao, X., Zhang, C., Cai, L., Cui, S., Wang, Y., and He, Y. (2012). Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032599"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Quinn, K., Traboni, C., Penchala, S.D., Bouliotis, G., Doyle, N., Libri, V., Khoo, S., Ashby, D., Weber, J., and Nicosia, A. (2017). A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-09230-0"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Angell, Y.M., Hartsock, W.J., and Reichart, T.M. (2022). Albuvirtide (Aikening), A gp41 Analog as an HIV-1 Fusion Inhibitor. Current Drug Synthesis, John Wiley & Sons, Inc.","DOI":"10.1002\/9781119847281.ch6"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2007.02.042","article-title":"Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide","volume":"129","author":"Adermann","year":"2007","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"63re3","DOI":"10.1126\/scitranslmed.3001697","article-title":"Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide","volume":"2","author":"Forssmann","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ding, H., Zhang, J., Zhang, F., Xu, Y., Yu, Y., Liang, W., and Li, Q. (2022). Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.990877"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.1200\/JCO.2023.41.16_suppl.6028","article-title":"Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy","volume":"41","author":"Kong","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_88","first-page":"1191","article-title":"Viral infections: Negative regulators of apoptosis and oncogenic factors","volume":"85","author":"Zamaraev","year":"2020","journal-title":"Biochemistry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41467-023-44455-w","article-title":"Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex","volume":"15","author":"Giehler","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1128\/JVI.05747-11","article-title":"Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells","volume":"86","author":"Ndour","year":"2012","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s40121-023-00889-9","article-title":"Candida albicans and antifungal peptides","volume":"12","author":"Freitas","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Vila, T., Sultan, A.S., Montelongo-Jauregui, D., and Jabra-Rizk, M.A. (2020). Oral candidiasis: A disease of opportunity. J. Fungi, 6.","DOI":"10.3390\/jof6010015"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Memariani, M., and Memariani, H. (2024). Antifungal properties of cathelicidin LL-37: Current knowledge and future research directions. World J. Microbiol. Biotechnol., 40.","DOI":"10.1007\/s11274-023-03852-5"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/wrr.12211","article-title":"Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: A randomized, placebo-controlled clinical trial","volume":"22","author":"Mahlapuu","year":"2014","journal-title":"Wound Repair Regen."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Cie\u015blik, M., Bagi\u0144ska, N., G\u00f3rski, A., and Jo\u0144czyk-Matysiak, E. (2021). Human \u03b2-defensin 2 and its postulated role in modulation of the immune response. Cells, 10.","DOI":"10.3390\/cells10112991"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Koeninger, L., Armbruster, N.S., Brinch, K.S., Kjaerulf, S., Andersen, B., Langnau, C., Autenrieth, S.E., Schneidawind, D., Stange, E.F., and Malek, N.P. (2020). Human \u03b2-defensin 2 mediated immune modulation as treatment for experimental colitis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00093"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Ul Haq, I., Maryam, S., Shyntum, D.Y., Khan, T.A., and Li, F. (2024). Exploring the frontiers of therapeutic breadth of antifungal peptides: A new avenue in antifungal drugs. J. Ind. Microbiol. Biotechnol., 51.","DOI":"10.1093\/jimb\/kuae018"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/13543784.2022.2086120","article-title":"Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action","volume":"31","author":"Hoenigl","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e0234520","DOI":"10.1128\/AAC.02345-20","article-title":"Preliminary Characterization of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity","volume":"65","author":"Duncan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Robles, E.M., Gir\u00f3n, R., Paniagua, N., Rodr\u00edguez-Rivera, C., Pascual, D., and Goicoechea, C. (2021). Monoclonal antibodies for chronic pain treatment: Present and future. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910325"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08923973.2021.2023173","article-title":"The role of TNF-\u03b1 and anti-TNF-\u03b1 agents in the immunopathogenesis and management of immune dysregulation in primary immunodeficiency diseases","volume":"44","author":"Abubakar","year":"2022","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-immunol-042617-053318","article-title":"Host control of fungal infections: Lessons from basic studies and human cohorts","volume":"36","author":"Lionakis","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jamainternmed.2021.0392","article-title":"Tocilizumab in treatment for patients with COVID-19","volume":"181","author":"Yang","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3109\/s10165-011-0449-0","article-title":"Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab","volume":"21","author":"Honda","year":"2011","journal-title":"Mod. Rheumatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cmi.2022.02.027","article-title":"Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study","volume":"28","author":"Broman","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Cavalli, G., and Dinarello, C.A. (2018). Anakinra therapy for non-cancer inflammatory diseases. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01157"},{"key":"ref_107","first-page":"1003","article-title":"Inflammasome in dendritic cells immunobiology: Implications to diseases and therapeutic strategies","volume":"18","author":"Ferreira","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1073\/pnas.1322831111","article-title":"IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans","volume":"111","author":"Smeekens","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1038\/ncomms10791","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis","volume":"7","author":"Iannitti","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/bloodadvances.2020002417","article-title":"Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection","volume":"5","author":"Yoshimori","year":"2021","journal-title":"Blood Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.4049\/jimmunol.1101868","article-title":"Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: A novel candidate for HIV neuroprotection","volume":"187","author":"Cross","year":"2011","journal-title":"J. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/imr.12280","article-title":"The interplay between inflammasome activation and antifungal host defense","volume":"265","author":"Joosten","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic\u2013pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Mochn\u00e1\u010dov\u00e1, E., Bhide, K., Kuckov\u00e1, K., Jozefiakov\u00e1, J., Ma\u013earik, T., and Bhide, M. (2025). Antimicrobial cyclic peptides effectively inhibit multiple forms of Borrelia and cross the blood-brain barrier model. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-90605-z"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharm. Res."},{"key":"ref_116","first-page":"662","article-title":"Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques","volume":"132","author":"Nellan","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ddr.21832","article-title":"Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability","volume":"82","author":"Verma","year":"2021","journal-title":"Drug Dev. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"111029","DOI":"10.1016\/j.isci.2024.111029","article-title":"Conjugated therapeutic proteins as a treatment for bacteria which trigger cancer development","volume":"27","author":"Halawa","year":"2024","journal-title":"iScience"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/mt.2016.175","article-title":"Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody\u2013drug conjugate","volume":"24","author":"Yu","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13075-024-03452-0","article-title":"Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenies of rheumatoid arthritis","volume":"26","author":"Dixit","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Boersma, B., Poinot, H., and Pommier, A. (2024). Stimulating the antitumor immune response using immunocytokines: A preclinical and clinical overview. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16080974"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7150\/thno.20047","article-title":"A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Boroumand, H., Badie, F., Mazaheri, S., Seyedi, Z.S., Nahand, J.S., Nejati, M., Baghi, H.B., Abbasi-Kolli, M., Badehnoosh, B., and Ghandali, M. (2021). Chitosan-based nanoparticles against viral infections. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.643953"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2174\/1871520615666150302125448","article-title":"Advances in the development of site-specific antibody-drug conjugation","volume":"15","author":"Zhou","year":"2015","journal-title":"Anti-Cancer Agents Med. Chem.-Anti-Cancer Agents"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody\u2013drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","article-title":"Antibody conjugate therapeutics: Challenges and potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1208\/s12248-012-9388-8","article-title":"Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics","volume":"14","author":"Xu","year":"2012","journal-title":"AAPS J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/jb\/mvaa116","article-title":"Glycosylation decreases aggregation and immunogenicity of adalimumab Fab secreted from Pichia pastoris","volume":"169","author":"Nakamura","year":"2021","journal-title":"J. Biochem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-013-0064-z","article-title":"Pegylation of biological molecules and potential benefits: Pharmacological properties of certolizumab pegol","volume":"28","author":"Pasut","year":"2014","journal-title":"BioDrugs"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"102624","DOI":"10.1016\/j.chempr.2025.102624","article-title":"Protein-based nanomedicines for cancer theranostics: From supramolecular self-assembly to AI-driven design and applications","volume":"11","author":"Cheng","year":"2025","journal-title":"Chem"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Alzhikeyeva, A., Yazici, A., and Sultankulov, B. (2025). Enzyme Engineering and Its Applications in Cancer Therapies: A Review of Machine Learning Approaches. Preprints.","DOI":"10.20944\/preprints202507.1406.v1"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Lorenc-KuKu, K. (2025). Cutting-edge AI tools revolutionizing scientific research in life sciences. BioTechnologia, 106.","DOI":"10.5114\/bta\/200803"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:03:29Z","timestamp":1763028209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":133,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pharmaceutics17111466"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17111466","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}